Part No: AN886Issued year: 2017File size: 1mbFile type: pdf
This application note describes the extraction of 96 licit and illicit drugs of abuse from urine prior to UPLC-MS/MS analysis using EVOLUTE® HYDRO CX 96-well plates.
EVOLUTE® HYDRO CX plates offer an efficient way to perform hydrolysis in the well of the extraction plate. This method provides high analyte recovery, reduced extraction time due to the elimination of a sample transfer step as well as the elimination of the column conditioning and equilibration steps, and a reduced risk for sample carryover or cross-contamination due to the elimination of the sample transfer step.
Part No: P163Issued year: 2017File size: 0.58mbFile type: pdf
Over the past decade, the need for non-invasive drug screening that that precludes sample adulteration has become attractive. As a result, detection using oral fluid devices for Drugs of Abuse (DOA) has come to the vanguard of the scientific community. The use of Supported Liquid Extraction (ISOLUTE® SLE+) prior to LC/MS or GC/MS can improve sample cleanliness without forfeiting sample detection within a diverse panel of DOAs. Here, we demonstrate the effects of altering elution solvent polarity and pH for sample pretreatment upon the simultaneous recovery of 34 compounds comprised of opioids, benzodiazepines, and stimulants to directly measure the effects of the oral fluid buffer, OraSure™, upon extraction and signal intensity at presumed LOQs.
Part No: P195Issued year: 2019File size: 0.8mbFile type: pdf
This poster shows an extraction protocol for 12 common drugs of abuse (DOA) to be detected in breast milk using mixed-mode polymeric cation exchange solid phase extraction (SPE).
Using the combination of reliable automation (on Biotage Extrahera) and SPE sample preparation techniques, a method was developed demonstrating the precision, accuracy, linearity, and sensitivity necessary for a robust quantitative workflow.
MSACL NA 2019
Part No: PPS443.V.1Issued year: 2019File size: 2.98mbFile type: pdf
Analysis of drug panels in urine samples can be challenging, and the trend towards larger panels including multiple drug classes compounds the issues faced during method development.
This white paper examines a number of aspects of sample preparation, and their impact on the success of subsequent LC-MS/MS analysis of broad urine panels.
Section 1 examines the applicability of various sample preparation techniques: supported liquid extraction, reverse phase SPE and mixed-mode SPE, to the various classes of drugs extracted. In addition, hydrolysis approaches: enzyme type and protocol used (time, temperature), are compared.
Mixed-mode reverse phase/cation exchange SPE is widely used for extraction of basic drug classes from urine, but the inclusion of drugs and metabolites that exhibit ‘non-typical’ functionality within urine panels can be problematic. Section 2 examines the impact of various parameters (interference wash strength, elution solvent composition) on analyte retention, elution and extract cleanliness with particular focus on zwitterionic (gabapentin, pregabalin) and non-ionic (carisoprodol, meprobamate) drugs.
Part No: P112Issued year: 2014File size: 1.4mbFile type: pdf
This poster demonstrates the extraction of a range of drugs of abuse from oral fluid, collected with common collection devices, prior to UPLC-MS/MS analysis. The target analyte list includes benzodiazepines, z drugs, amphetamines, cathinones, opiates, cocaine, buprenorphine, PCP, THC-COOH, fentanyl and ketamine.
Part No: P132Issued year: 2015File size: 1.55mbFile type: pdf
This poster demonstrates the extraction of a range of drugs of abuse from oral fluid collection devices using supported liquid extraction suitable for UPLC-MS/MS analysis. Unlike some sample preparation techniques, SLE allows for the simultaneous extraction of cross-functional analytes in a single extraction protocol without forfeiting extract cleanliness.
The target analyte list includes benzodiazepines, z drugs, amphetamines, cathinones, opiates, cocaine, buprenorphine, PCP, THC-COOH, fentanyl and ketamine.
Part No: P087Issued year: 2014File size: 0.94mbFile type: pdf
This poster describes the extraction of a range of drugs of abuse (including barbiturates, THC and metabolites, benzodiazepines, z drugs, amphetamines,cathinones, opiates, cocaine, buprenorphine, PCP, fentanyl and ketamine) from oral fluid using supported liquid extraction (ISOLUTE SLE+) columns prior to GC-MS and LC-MS/MS analysis.
Part No: P151Issued year: 2016File size: 0.96mbFile type: pdf
This poster compares the performance of manual processing to a novel automated sample preparation system prior to GC/MS or LC-MS/MS analysis in forensic toxicology applications. Emphasis is placed on the potential for 96-well cross contamination and strategies for its elimination.
Part No: P156Issued year: 2017File size: 0.23mbFile type: pdf
Most drugs are excreted in urine as glucuronide conjugates. Hydrolysis using a beta-glucuronidase enzyme to convert the metabolites to their “free” form for analysis increases sensitivity. Red abalone (Kura Biotech), abalone (Campbell Scientific), and recombinant (IMCSzyme) beta-glucuronidase enzymes were evaluated to determine which provided the most complete hydrolysis of glucuronide metabolites without effecting the overall recovery of non-conjugated compounds.
EVOLUTE EXPRESS CX 96-well plates were used to extract hydrolysed urine samples, and the impact of th enzymes was compared.
MSACL 2017, Palm Springs
SOFT 2017, Boca Raton
Part No: AN832Issued year: 2014File size: 1.78mbFile type: pdf
This application note describes the extraction of 47 drugs of abuse from oral fluid matrix after sampling via Quantisal collection devices prior to analysis by UPLC-MS/MS. Optimised protocols for 200 uL and 500 uL sample volumes are included.
Part No: AN836Issued year: 2015File size: 1.81mbFile type: pdf
This application note describes the extraction of 47 drugs of abuse and metabolites from oral fluid matrix collected using the Intercept Oral Fluid Drug Test Kit (Orasure Technologies), prior to UPLC-MS/MS analysis. The sample preparation is optimised to minimise matrix effects due to the buffers used in the collection device. Estimated LOQs range from 0.1-1 ng/mL for the various analytes.
Part No: AN837Issued year: 2015File size: 2.27mbFile type: pdf
This application note describes the extraction of 47 drugs
of abuse and metabolites from oral fluid matrix after sampling via Oral-Eze collection devices, prior to UPLC-MS/MS analysis using ISOLUTE SLE+ supported liquid extraction columns. Estimated LOQs of between 0.005 and 0.75 ng/mL (analyte dependant) are achieved,.
Part No: AN875Issued year: 2017File size: 3.36mbFile type: pdf
This application note describes the extraction, using ISOLUTE SLE+ supported liquid extraction columns, of 49 drugs of abuse from whole blood, prior to UPLC-MS/MS analysis.
High, reproducible drug recoveries are achieved, with sub ng/mL LOQs for most analytes. The method is easily automated using Biotage® Extrahera.
Part No: AN915Issued year: 2019File size: 1.53mbFile type: pdf
This application note describes the extraction of 25 illicit and prescribed drugs from hydrolyzed urine using ISOLUTE® HYDRO DME+ Dual Mode Extraction plates prior to UPLC-MS/MS analysis.
Because of the enhanced sample clean up delivered by ISOLUTE HYDRO DME+ products, analyte sensitivity is significantly increased compared to traditional dilute and shoot (D&S) techniques, resulting in reduced limits of quantitation (LOQ)
Part No: IST1019AIssued year: 2011File size: 0.14mbFile type: pdf
This method was developed for the extraction of phencyclidine from meconium for drugs ofabuse applications. The analyte has an ionisable amine group, which is exploited through cation exchange interactions. The pKa is approximately 8, so the compound is fully ionized at pH values of less than 6. The analyte also has significant non-polar characteristics, and both hydrophobic and ion exchange retention mechanisms are used to give a clean extract.
ISOLUTE, PCP, DOA, Varian Bond Elut Certify, UCT CleanScreen DAU
Part No: IST1039AIssued year: 2011File size: 0.14mbFile type: pdf
This application was developed for the extraction of phencyclidine and other basic drugs from urine for drugs of abuse applications. Typical recovery for PCP is > 85%.
PCP, DOA, Biotage, ISOLUTE, UCT CleanScreen DAU, Varian Bond Elut Certify
Part No: AN007-HORIssued year: 2009File size: 0.64mbFile type: pdf
EPA Method 515.2 is applicable to the determination of
chlorinated acids in ground water and finished drinking
water. The form of each acid is not distinguished by this
method. Results are calculated and reported for each listed analyte as the total free acid. The analytes are extracted from the water using a DVB-Hydrophobic disk and the Horizon Technology SPE-DEXÒ 4770 Automated
Extraction System. The disk is extracted with Methylene
Chloride and the extract dried with sodium sulfate. The
extract is derivatized with diazomethane. Final analysis is by GC/ECD.
Part No: AN898Issued year: 2018File size: 1.91mbFile type: pdf
This application note describes a procedure for sample
pre-treatment and extraction of a panel of 49 drugs of
abuse from human hair, using Biotage® Lysera for matrix
micropulverization, prior to clean up using ISOLUTE® SLE
supported liquid extraction. The application note contains
procedures optimized for 400 μL capacity column format and
200 μL and 400 μL supported liquid extraction plate formats,
for higher throughput applications. The methodology delivers
clean extracts and analyte recoveries mostly greater than
80% with RSDs lower than 10% for all analytes and LLOQ from